Day One Biopharmaceuticals (NASDAQ:DAWN) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Day One Biopharmaceuticals (NASDAQ:DAWN) in a report issued on Tuesday morning, Benzinga reports. They currently have a $33.00 price objective on the stock.

Several other brokerages have also recently commented on DAWN. Oppenheimer reiterated a market perform rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. The Goldman Sachs Group decreased their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating on the stock in a research report on Tuesday, February 27th. Piper Sandler restated an overweight rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. JPMorgan Chase & Co. upped their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an overweight rating in a research report on Monday, April 22nd. Finally, HC Wainwright decreased their target price on shares of Day One Biopharmaceuticals from $50.00 to $40.00 and set a buy rating on the stock in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus price target of $37.67.

Day One Biopharmaceuticals Stock Up 2.9 %

Shares of DAWN stock opened at $17.08 on Tuesday. The stock has a market cap of $1.49 billion, a P/E ratio of -7.18 and a beta of -1.44. Day One Biopharmaceuticals has a 52 week low of $9.67 and a 52 week high of $18.07. The company’s fifty day simple moving average is $15.47 and its two-hundred day simple moving average is $14.12.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). On average, analysts anticipate that Day One Biopharmaceuticals will post -2.67 EPS for the current fiscal year.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 2,666 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $40,656.50. Following the transaction, the chief financial officer now directly owns 277,754 shares in the company, valued at approximately $4,235,748.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Charles N. York II sold 52,183 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $17.89, for a total transaction of $933,553.87. Following the transaction, the chief financial officer now directly owns 225,571 shares in the company, valued at $4,035,465.19. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Charles N. York II sold 2,666 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $40,656.50. Following the transaction, the chief financial officer now owns 277,754 shares in the company, valued at $4,235,748.50. The disclosure for this sale can be found here. Insiders have sold 195,247 shares of company stock worth $3,376,817 in the last three months. Corporate insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Arizona State Retirement System boosted its stake in Day One Biopharmaceuticals by 8.8% in the third quarter. Arizona State Retirement System now owns 12,363 shares of the company’s stock valued at $152,000 after acquiring an additional 995 shares in the last quarter. Quintet Private Bank Europe S.A. lifted its stake in Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after acquiring an additional 1,000 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after acquiring an additional 1,262 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in shares of Day One Biopharmaceuticals by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock worth $979,000 after acquiring an additional 1,445 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in shares of Day One Biopharmaceuticals by 9.7% during the third quarter. Principal Financial Group Inc. now owns 17,781 shares of the company’s stock worth $218,000 after purchasing an additional 1,569 shares during the last quarter. 87.95% of the stock is currently owned by institutional investors.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.